Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640047 | 0.86 | KMT2A (0.43) | DYRK1AAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL1104637 | 0.74 | PARP1 (0.43) | PIM1RPS6KA3BTKKDM4EALDH1A1 | |
| SCHEMBL17597488 | 0.74 | ALDH1A1 (0.43) | JAK2KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL30770814 | 0.74 | PRKCI (0.44) | DYRK1AABL1RPS6KA3NTRK1BTK | |
| SCHEMBL14858747 | 0.74 | PARP1 (0.39) | CDK5GSK3AGSK3BKDM4EALDH1A1 | |
| SCHEMBL23731797 | 0.74 | KDM4E (0.33) | KDM4EALDH1A1MAPTMAPK1APEX1 | |
| SCHEMBL14858833 | 0.74 | PARP1 (0.39) | KDM4EALDH1A1MAPTCSNK2A1MAPK1 | |
| SCHEMBL986400 | 0.74 | PRKCI (0.44) | DYRK1AABL1RPS6KA3NTRK1BTK | |
| SCHEMBL10131569 | 0.74 | DYRK1A (0.46) | DYRK1AAURKAJAK2MAP4K4FGFR1 | |
| Hydrochloric Acid SCHEMBL1365384 | 0.72 | KDM4E (0.46) | ABL1RPS6KA3BTKKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4642450-A2 | EP2 ANTAGONIST COMPOUNDS | Reservoir Neuroscience, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4547662-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | DYRK1A 879/4885AURKA 142/4885JAK2 94/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | DYRK1A 1637/4885AURKA 309/4885JAK2 1049/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | DYRK1A 879/4885AURKA 142/4885JAK2 94/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | DYRK1A 3578/4885AURKA 2330/4885JAK2 531/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | DYRK1A 3699/4885AURKA 2765/4885JAK2 157/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | DYRK1A 2817/4885AURKA 3376/4885JAK2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.